Share on StockTwits

Gilead Sciences (NASDAQ:GILD) CFO Robin L. Washington sold 3,000 shares of the company’s stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $79.91, for a total value of $239,730.00. Following the completion of the sale, the chief financial officer now directly owns 49,832 shares in the company, valued at approximately $3,982,075. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of Gilead Sciences (NASDAQ:GILD) traded down 0.05% during mid-day trading on Thursday, hitting $78.73. 13,780,564 shares of the company’s stock traded hands. Gilead Sciences has a 52-week low of $46.70 and a 52-week high of $84.88. The stock’s 50-day moving average is $73.03 and its 200-day moving average is $74.90. The company has a market cap of $121.1 billion and a P/E ratio of 29.17.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, April 22nd. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.63. The company had revenue of $5.00 billion for the quarter, compared to the consensus estimate of $3.80 billion. During the same quarter in the previous year, the company posted $0.48 earnings per share. The company’s revenue for the quarter was up 97.5% on a year-over-year basis. On average, analysts predict that Gilead Sciences will post $6.21 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on GILD shares. Analysts at Maxim Group raised their price target on shares of Gilead Sciences from $101.00 to $112.00 in a research note on Monday, April 28th. They now have a “buy” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Gilead Sciences in a research note on Thursday, April 24th. They now have a $78.00 price target on the stock. Finally, analysts at Nomura reiterated a “buy” rating on shares of Gilead Sciences in a research note on Wednesday, April 23rd. They now have a $130.00 price target on the stock. Four analysts have rated the stock with a hold rating and twenty-two have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $89.18.

Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.